BTA 0.00% 57.0¢ biota holdings limited

what a great resolution for shareholders!, page-10

  1. 3,045 Posts.
    Hi QF

    Here it is:

    "CEO Peter Cook
    First, we’ll be very carefully monitoring Relenza royalties each quarter and
    informing our shareholders about that. Second, with laninamavir we’d expect
    to see progress towards a rest-of-the-world partner and also to see progress
    toward the commercial introduction of the product in Japan, including the
    NDA submission and commencement of the prophylaxis study. Additionally,
    we’ll see progress on the clinical studies of laninamivir underway in the West.
    Third, we’d expect to see progress on the licensing of the HRV program and
    fourth we’d expect progress around the Hepatitis C program we’ve licensed to
    Boehringer Ingelheim, which we’ve not had a lot to say about in the recent
    period.
    In addition, we’ve spent a considerable amount of time on strategy in the last
    few months and we’ve identified that as quickly as possible we want to be in
    the position of having two or three products out in the market generating
    royalties at any one point in time. That’s going to require the addition of
    appropriate programs to our portfolio.
    corporatefile."

    http://www.biota.com.au/uploaded/154/1021550_52openbriefing-ceoonfy09r.pdf
 
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.